GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Candidates for antiviral therapy include those who are in the immune clearance (hepatitis B e antigen [HBeAg]-positive) or reactivation (HBeAg-negative) phases. Hepatitis B & hepatocellular ...

Background In chronic hepatitis B patients, an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase’s natural history and prognosis, ...

Patients with CHB in the indeterminate phase have incidence rates of hepatic decompensation, cirrhosis, and liver cancer. Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains ... are asymptomatic during the early and chronic stages of infection even as the virus, one of the smallest ...

Barinthus Biotherapeutics has shared its most significant recent data from the ongoing Phase IIb HBV003 clinical trial for chronic hepatitis B. The newest data was cut off on 30 September (for lab ...

Background Increasing evidence suggests that the gut microbiota has evolved as a new important player in the pathogenesis of hepatitis B virus-induced chronic liver disease ... influence which ...

Twenty-seven patients with Chronic Hepatitis B Virus infection (CHB ... intramuscular (i.m.) injection VRON-0200 is a Phase 1b, multi-center, open-label, dose escalation, prime only, and prime ...

"GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...